^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

miR-34a expression

i
Other names: MIR34A, mir-34, MIRN34A, mir-34a, miRNA34A
Entrez ID:
Related biomarkers:
1year
Lower expressions of MIR34A and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment. (PubMed, Pathol Res Pract)
Lower MIR34A and MIR31 levels are associated with higher TILs density in CRC. Unlike other cancers where MIR34A has anti-tumour effects, there was no statistically significant correlation between its expression and the pT or TNM stages in this study. Increased TILs being a good prognostic indicator, this suggests MIR34A and MIR31 may help CRC cells evade immune surveillance. Aberrant p53 expression downregulates MIR34A, underscoring the therapeutic potential of miRs.
Journal
|
TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR31 (MicroRNA 31)
|
TP53 expression • CTNNB1 expression • miR-34a expression • miR-34a underexpression
1year
MicroRNA-34a negatively regulates Netrin1 and mediates MEK/ERK pathway to regulate chemosensitivity of gastric cancer cells. (PubMed, Discov Oncol)
miR-34a targets and negatively regulates Netrin1 to mediate the proliferation, apoptosis, apoptosis, migration, and invasion of drug-resistant gastric cancer cells via the MEK/ERK pathway, and change the chemosensitivity in GC cells. miR-34a/Netrin1/MEK/ERK axis may serve as a novel therapeutic target for chemoresistance in GC, it is of great significance for overcoming drug resistance and developing new therapeutic strategies for GC.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CDH1 (Cadherin 1) • MIR34A (MicroRNA 34a-5p) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • NTN1 (Netrin 1)
|
CDH1 expression • MAPK1 overexpression • miR-34a expression
|
cisplatin
1year
Regulatory role and molecular mechanism of METTL14 in vascular endothelial cell injury in preeclampsia. (PubMed, Biomol Biomed)
Overexpression of miR-34a-5p or silencing of FOXP1 reversed the protective effects of METTL14 silencing on cell injury in the PE model. In conclusion, METTL14 mediated m6A modification to promote miR-34a-5p expression, leading to the inhibition of FOXP1 expression, which aggravated endothelial cell damage in the PE cell model.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ICAM1 (Intercellular adhesion molecule 1) • MIR34A (MicroRNA 34a-5p) • FOXP1 (Forkhead Box P1) • VCAM1 (Vascular Cell Adhesion Molecule 1) • METTL14 (Methyltransferase 14)
|
miR-34a expression • miR-34a overexpression • miR-34a underexpression
over1year
Blocking lncRNA HCG18 re-sensitizes Taxol resistant lung cancer cells to Taxol through modulating the miR-34a-5p/HDAC1 axis. (PubMed, J Chemother)
In conclusion, our in vitro and in vivo results uncover a novel molecular mechanism by which HCG18 promotes Taxol resistance through modulation of the miR-34a-5p/HDAC1 axis. These findings contribute to the diagnosis and treatment of chemo-resistant lung cancer.
Journal
|
MIR34A (MicroRNA 34a-5p) • HDAC1 (Histone Deacetylase 1)
|
miR-34a expression
|
paclitaxel
over1year
Bioinformatics study and experimental evaluation of miR-182, and miR-34 expression profiles in Tuberculosis and lung cancer. (PubMed, Tuberc Respir Dis (Seoul))
Reducing the expression pattern of these microRNAs indicates their role in lung cancer and tuberculosis occurrence. Therefore, these microRNAs can be used as a biomarker for prognosis, diagnosis, and treatment methods.
Journal
|
MIR34A (MicroRNA 34a-5p) • MIR182 (MicroRNA 182)
|
miR-34a expression
over1year
Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors. (PubMed, Oncol Lett)
Plasma-based expression of miR-21, -34a, -193b, -200a and -200b effectively distinguished patients with ABC who responded to CDK4/6i treatment from patients who were resistant. However, longitudinal studies are required to verify the predictive and prognostic potential of miRNA.
Journal • Liquid biopsy • Metastases • Biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • MIR200B (MicroRNA 200b) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR193B (MicroRNA 193b) • MIR200A (MicroRNA 200a)
|
miR-34a expression
almost2years
An In Vitro Study for the Role of Schizophrenia-Related Potential miRNAs in the Regulation of COMT Gene. (PubMed, Mol Neurobiol)
RNA-IP data have shown that the amount of COMT pulled down by Ago2 was increased after miR-30a-5p and miR-34a-5p transfections. RNA-IP results revealed that miR-30a-5p and miR-34a-5p are direct targets for the COMT gene.
Preclinical • Journal
|
MIR34A (MicroRNA 34a-5p) • MIR30A (MicroRNA 30a) • MIR30E (MicroRNA 30e) • COMT (Catechol-O-Methyltransferase)
|
miR-34a expression
almost2years
Impact of Long-Lasting Environmental Factors on Regulation Mediated by the miR-34 Family. (PubMed, Biomedicines)
Moreover, the apoptogenic capacity of miR-34 induced via phthalate administration in the testes has been shown to negatively influence germ cell proliferation. To conclude, as the oncostatic and positive neuromodulatory functions of the miR-34 family can be strongly influenced by environmental factors, their interactions should be taken into consideration in translational medicine.
Review • Journal
|
CCND1 (Cyclin D1) • MIR34A (MicroRNA 34a-5p) • CRY1, Cryptochrome Circadian Regulator 1, • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCND1 expression • CRY1 mutation • miR-34a expression
almost2years
Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia. (PubMed, Oncol Res)
miR-34a could be a beneficial diagnostic biomarker for AML patients. In addition, it serves as a good indicator for response to therapy, which could possibly identify patients who are refractory to treatment with 100% sensitivity and 75% specificity.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
almost2years
Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo. (PubMed, Sci Rep)
In vivo, intratumor injection of miR-34a antagomir could drastically suppress the anti-tumor formation effects of acacetin in A549-xenografted nude mice. Overall, our results showed that acacetin inhibits cell proliferation and induces cell apoptosis of NSCLC cells by regulating miR-34a.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MIR34A (MicroRNA 34a-5p) • CCNB1 (Cyclin B1)
|
PD-L1 expression • TP53 expression • miR-34a expression
almost2years
MiR-34a functions as a tumor suppressor in oral cancer through the inhibition of the Axl/Akt/GSK-3β pathway. (PubMed, J Dent Sci)
Our findings highlight the significance of the miR-34a/Axl/Akt/GSK-3β signaling axis in modulating the malignancy of oral cancer cells. Targeting miR-34a may hold therapeutic potential in oral cancer treatment, as manipulating its expression can attenuate the aggressive behavior of oral cancer cells via the Axl/Akt/GSK-3β pathway.
Journal
|
AXL (AXL Receptor Tyrosine Kinase) • MIR34A (MicroRNA 34a-5p)
|
AXL overexpression • miR-34a expression • miR-34a overexpression • miR-34a underexpression
almost2years
HDAC6-MYCN-CXCL3 axis mediates allergic inflammation and is necessary for allergic inflammation-promoted cellular interactions. (PubMed, Mol Immunol)
Recombinant CXCL3 protein also increased the expression of markers of M2 macrophage. Thus, the identification of the novel role of HDAC6-MYCN-CXCL3 axis can help better understand the pathogenesis of anaphylaxis.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MIR34A (MicroRNA 34a-5p) • HDAC6 (Histone Deacetylase 6) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
|
MYC expression • HDAC6 expression • miR-34a expression